20 unknown. 20 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Unknown 20 |
| Phase 2 | 8 | Unknown 8 |
Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis. GR2002 injection - Atopic Dermatitis | Phase 1 | Unknown | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 40 | 2023-12-01 | 2023-12-18 |
| A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults FB825 or Placebo in subcutaneous route, FB825 in intravenous route - Atopic Dermatitis | Phase 1 | Unknown | Oneness Biotech Co., Ltd. | 22 | 2023-05-03 | 2024-01-26 |
| A First-in-Human Study of QY211 Gel in Adult Subjects 0.1% QY211 Gel or placebo, 0.3% QY211 Gel or placebo, 0.8% QY211 Gel or placebo - Atopic Dermatitis | Phase 1 | Unknown | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | 56 | 2023-03-01 | 2023-05-06 |
| Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Single Dose, Double Dose - Chronic Conjunctivitis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Unknown | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 20 | 2022-11-11 | 2024-07-08 |
| A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis 2mg QY201 tablets or 2mg QY201 placebo,BID, 5mg QY201 tablets or 5mg QY201 placebo,BID, 10mg QY201 tablets or 10mg QY201 placebo,QD - Atopic Dermatitis | Phase 1 / Phase 2 | Unknown | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | 260 | 2022-10-01 | 2022-09-02 |
| A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects TQH2722 injection, Placebo to match TQH2722 - Atopic Dermatitis | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 48 | 2022-06-01 | 2022-06-08 |
| BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma) Sapropterin dihydrochloride tablets - Head and Neck Squamous Cell Carcinoma | Phase 1 | Unknown | West China Hospital | 18 | 2022-05-01 | 2022-03-28 |
| SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects RBN-3143 - Atopic Dermatitis | Phase 1 | Unknown | Ribon Therapeutics, Inc. | 72 | 2022-03-07 | 2023-10-23 |
| A Study for Assessing the Efficacy and Safety of Tetrahydrobiopterin in Radiation-Induced Skin Injury Tetrahydrobiopterin - Radiation-Induced Dermatitis | Phase 1 | Unknown | West China Second University Hospital | 45 | 2022-03-01 | 2022-02-28 |
| A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB PDC-APB, Placebo - Contact Dermatitis | Phase 1 | Unknown | Hapten Sciences, Inc. | 32 | 2021-11-01 | 2021-08-27 |
| MH004 Topical Cream in Healthy Adult Volunteers and Participants With Atopic Dermatitis or Rheumatoid Arthritis MH004 Ia(0.1%), MH004 Ia(0.3%), MH004 Ia(1%) - Atopic Dermatitis, Rheumatoid Arthritis | Phase 1 | Unknown | Minghui Pharmaceutical Pty Ltd | 72 | 2021-04-01 | 2021-03-24 |
| Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis FURESTEM-AD inj - Atopic Dermatitis | Phase 1 / Phase 2 | Unknown | Kang Stem Biotech Co., Ltd. | 96 | 2021-01-27 | 2022-01-11 |
| Efficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold. Mepitel® film, Flamigel® - Radiodermatitis, Radiation Toxicity | Phase 1 / Phase 2 | Unknown | Jules Bordet Institute | 35 | 2021-01-01 | 2020-11-05 |
| Topical Cream SNG100 for Treatment in Moderate Atopic Dermatitis Subjects. Hydrocortisone Acetate 1% Cream, Mometasone Furoate, SNG100 - Atopic Dermatitis | Phase 1 | Unknown | Seanergy Dermatology Ltd. | 66 | 2021-01-01 | 2020-11-04 |
| Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis RVT-501 0.5% topical ointment - Atopic Dermatitis | Phase 1 | Unknown | Dermavant Sciences GmbH | 24 | 2018-02-05 | 2018-05-11 |
| Ganoderma Tea on Eczema Patient A Master Ganoderma Detox Tea - Eczema | Phase 1 / Phase 2 | Unknown | Hong Kong Baptist University | 30 | 2015-08-01 | 2015-08-27 |
| MARY DUOL REPAIR BALM IN THE PREVENTION OR REDUCING ANTINEOPLASIC AGENTS' SKIN TOXICITY BALM ARM, PLACEBO ARM - Dermatitis, Adverse Drug Reaction | Phase 1 / Phase 2 | Unknown | Basque Health Service | 86 | 2014-02-01 | 2016-08-02 |
| Evaluation of A-1 Cool Cream Efficacy for Treatment Atopic Dermatitis A -1 Cool Cream,Vaselin ointment - ATOPIC DERMATITIS | Phase 1 / Phase 2 | Unknown | Hadassah Medical Organization | 30 | 2011-07-01 | 2011-07-06 |
| Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients Botulinum toxin - Parkinson Disease, Parkinsonism | Phase 1 | Unknown | Rabin Medical Center | 40 | 2009-05-01 | 2008-10-07 |
| Olive Oil With Omega 3 to Treat Stasis Dermatitis olive oil and omega 3 in a combined cream - Dermatitis | Phase 1 / Phase 2 | Unknown | Assaf-Harofeh Medical Center | 30 | 2007-01-01 | 2007-01-11 |
Dermatitis, Atopic (11) · Radiodermatitis (3) · Arthritis, Rheumatoid (1) · Dermatitis, Contact (1) · Dermatitis, Seborrheic (1) · Drug Eruptions (1) · Eczema (1) · Nasopharyngeal Carcinoma (1) · Parkinson Disease (1) · Parkinsonian Disorders (1) · Pemphigoid, Bullous (1) · Radiation Injuries (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stevens-Johnson Syndrome (1)
Skin Diseases (20) · Skin and Connective Tissue Diseases (20) · Skin Diseases, Eczematous (14) · Hypersensitivity (12) · Immune System Diseases (12) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Genetic Diseases, Inborn (11) · Hypersensitivity, Immediate (11) · Skin Diseases, Genetic (11) · Wounds and Injuries (3) · Autoimmune Diseases (2) · Chemically-Induced Disorders (2) · Drug Hypersensitivity (2) · Drug-Related Side Effects and Adverse Reactions (2)
sapropterin (2) · Botulinum Toxins (1) · Docosahexaenoic Acids (1) · Exercise (1) · Injections, Subcutaneous (1) · Mometasone Furoate (1) · Ointments (1) · Olive Oil (1) · hydrocortisone acetate (1) · methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoate (1)
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (2) · Assaf-Harofeh Medical Center (1) · Basque Health Service (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · Dermavant Sciences GmbH (1) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. (1) · Hadassah Medical Organization (1) · Hapten Sciences, Inc. (1) · Hong Kong Baptist University (1) · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1) · Jules Bordet Institute (1) · Kang Stem Biotech Co., Ltd. (1) · Minghui Pharmaceutical Pty Ltd (1) · Oneness Biotech Co., Ltd. (1) · Rabin Medical Center (1)
China (4) · Spain (2) · United States (2) · Australia (1) · Hong Kong (1) · Israel (1) · New Zealand (1) · South Korea (1)
Arie Bass, MD (1) · Cheng Zhou, PHD (1) · James Lee, MD, PhD (1) · James Marks, MD (1) · Jianzhong Zhang, PHD (1) · LiMing Wu, Ph.D, M.D (1) · Patricia Seaone, MD (1) · Raquel Cobos, Msc (1) · Shi Ping Zhang, PhD (1) · Thomas Polasek, MD (1) · Xingchen Peng, Ph.D (1) · Yuval Ramot, Prof. (1)